【摘要】：目的觀察不同劑量非布司他與別嘌呤醇治療高尿酸血癥伴痛風的臨床療效及安全性。方法將90例高尿酸血癥伴痛風患者隨機分為試驗A組、試驗B組和對照組,每組30例。對照組患者予以口服別嘌呤醇片300 mg tid;試驗A組患者予以口服非布司他片35 mg qd,試驗B組患者予以口服非布司他片70mg qd,3組患者均治療24周。比較3組患者的臨床療效和藥物不良反應發(fā)生率,以及治療前、治療12周及24周時患者的血清可溶性細胞黏附因子-1(s ICAM-1)水平和尿酸水平。結果治療后,試驗A組、試驗B組和對照組的總有效率分別為56.67%(17例/30例),66.67%(20例/30例)和46.67%(14例/30例),差異均有統(tǒng)計學意義(均P0.05)。治療后12周,試驗A組、試驗B組和對照組的血清s ICAM-1分別為(445.76±135.85),(421.28±122.25)和(493.39±121.27)ng·mL~(-1);治療后24周,試驗A組、試驗B組和對照組的血清s ICAM-1分別為(387.71±126.75),(360.85±125.50)和(441.45±122.48)ng·mL~(-1),差異均有統(tǒng)計學意義(均P0.05);分別與治療前比較,差異均有統(tǒng)計學意義(均P0.05)。治療后12周,試驗A組、試驗B組和對照組的尿酸分別為(445.57±135.50),(460.60±140.45)和(515.20±142.15)ng·mL~(-1);治療后24周,試驗A組、試驗B組和對照組的尿酸分別為(425.10±126.28),(410.10±130.38)和(478.80±164.72)ng·mL~(-1),差異均有統(tǒng)計學意義(均P0.05);分別與治療前比較,差異均有統(tǒng)計學意義(均P0.05)。試驗組和對照組在治療過程中均未發(fā)生明顯藥物不良反應。結論非布司他可降低高尿酸血癥伴痛風患者的血清s ICAM-1水平和尿酸水平,臨床療效優(yōu)于別嘌呤醇。
[Abstract]:Objective to observe the efficacy and safety of different doses of nonbuflast and allopurinol in the treatment of hyperuricemia with gout. Methods 90 patients with hyperuricemia and gout were randomly divided into three groups: group A, group B and control group. Patients in the control group were treated with oral allopurinol 300 mg tid; test group A and group B were treated with non-busultam tablets for 35 mg qd,. The patients in the 70mg qd,3 group were treated for 24 weeks. The clinical efficacy and incidence of adverse drug reactions, serum soluble cell adhesion factor-1 (s ICAM-1) and uric acid levels were compared between the three groups before and after 12 and 24 weeks of treatment. Results after treatment, the total effective rates of group A, group B and control group were 56.67% (17 / 30), 66.67% (20 / 30) and 46.67% (14 / 30), respectively (P0.05). At 12 weeks after treatment, the serum s ICAM-1 levels in group A, group B and control group were (445.76 鹵135.85), () 421.28 鹵122.25 and (493.39 鹵121.27) ng mL~ (-1), respectively, and 24 weeks after treatment, those in group A were (445.76 鹵135.85), (鹵122.25) and (493.39 鹵121.27) ng mL~ (-1), respectively. The serum s ICAM-1 of group B and control group were (387.71 鹵126.75), (360.85 鹵125.50) and (441.45 鹵122.48) ng mL~ (P 0.05), respectively. At 12 weeks after treatment, uric acid levels in group A, group B and control group were (445.57 鹵135.50), (460.60 鹵140.45) and (515.20 鹵142.15) ng mL~ (-1), respectively, 24 weeks after treatment, uric acid in group A, group B and control group were (425.10 鹵126.28), (410.10 鹵130.38) and (478.80 鹵164.72) ng mL~ (-1), respectively. The difference was statistically significant (P0.05). There were no significant adverse drug reactions in the treatment process in both the experimental group and the control group. Conclusion the serum s ICAM-1 level and uric acid level in patients with hyperuricemia and gout can be decreased by using fentinast, and the clinical efficacy is better than that of allopurinol.
【作者單位】： 福建莆田學院附屬醫(yī)院藥劑科;福建省疾病預防控制中心;
【基金】：福建省衛(wèi)生計生委青年科研課題基金資助項目(2015-2-26)
【分類號】：R589.7

【相似文獻】

相關期刊論文 前10條

1 鄧云,梅春雪,饒進;高尿酸血癥知識強化教育在治療中的作用[J];四川醫(yī)學;2001年11期

2 李黎;高尿酸血癥97例臨床分析[J];中國誤診學雜志;2005年14期

3 楊玉霞;劉勇;;高尿酸血癥綜合系統(tǒng)管理分析[J];臨床和實驗醫(yī)學雜志;2006年06期

4 李玉珍;張曉華;;89例中老年人高尿酸血癥臨床分析[J];河北醫(yī)藥;2006年12期

5 呂才模;彭潔敏;劉曉燕;翟蓓;丁春艷;;烏魯木齊市漢族健康體檢者高尿酸血癥調查分析[J];內科;2009年06期

6 陳素芬;;高尿酸血癥患者疾病相關知識調查分析[J];護理管理雜志;2009年08期

7 楊聰;黃謙;馮國君;劉云祥;;西藏某地區(qū)體檢人群高尿酸血癥分析[J];西南國防醫(yī)藥;2010年02期

8 袁自宏;g，

本文編號：2264638